biotech investing argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
biotech investing argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
biotech investing argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
biotech investing argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
biotech investing argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
biotech investing argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada
biotech investing argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
biotech investing argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
biotech investing argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
CORRECTION FROM SOURCE: Video - CEO Clips Bold Ventures Advances Exploration at Burchell and Highlights Ring of Fire
Bold Ventures Provides Update on Burchell Drilling Progress and Announces PDAC Participation at Booth #2610
